PRESS RELEASEOMass Therapeutics Expands Development Team with Key Appointments in US and UK and Announces the Nomination of Clinical Candidate ...
Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
The US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback